Profile of Depressive Symptoms in Parkinsons Disease

Boehringer Ingelheim1,018 enrolled

Overview

To explore or establish the relationship between cognitive, mood and motor symptoms in PD to scores on depression rating scales in a naturalistic setting.

Study Type

OBSERVATIONAL

Enrollment

1,018

Conditions

Parkinson Disease Depression

Interventions

PramipexoleDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion\_Criteria: Observation criteria: * are able to provide written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * have idiopathic Parkinsons disease according to the United Kingdom Parkinsons Disease Society Brain Bank Diagnostic Criteria for Parkinsons disease * show no impairment of cognitive function (MMSE score ?24) * are with or without symptoms of depression (full range) * are stable on anti-Parkinson/anti-depressive treatment for at least 1 month before entering the study * are or are not on concomitant antidepressant treatment * are in the on state during the observation period * did not previously undergo PD surgery

Locations (24)

Boehringer Ingelheim Investigational Site

Innsbruck, Austria

Outcomes

Primary Outcomes

HADS, HAMD-17, BDI-1A, FAB (cognitive), DSM-IV (mood- part A, B, C, E) and UPDRS

Time frame: Up to 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.